18 completed, 15 unknown, 5 withdrawn, 4 terminated. 47 Phase 3, 19 Phase 2.
Follow Marijuana Abuse: new trials by email Literature Review of Marijuana Abuse trials Research Report on Marijuana Abuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Fenix Innovation Group | 40 | 2027-07-01 | 2026-09-09 |
| NTI164 in Autism Spectrum Disorder NTI164, Placebo - Autism, Autism Spectrum Disorder | Phase 3 | Not yet recruiting | Fenix Innovation Group | 200 | 2026-09-30 | 2026-09-30 |
| Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department Olanzapine 10 milligram, Haloperidol - Cannabinoid Hyperemesis Syndrome | Phase 3 | Completed | Mercy Bon Secours Saint Vincent Medical Center | 31 | 2025-11-06 | 2026-10-14 |
| Reducing Breathlessness With Dronabinol in COPD Patients Dronabinol 2.5mg Capsule, Placebo - COPD, Breathlessness | Phase 3 | Completed | Vejle Hospital | 30 | 2025-02-26 | 2026-10-05 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Adezunap, Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Adezunap (AP707), Placebo - Pain, Pain Syndrome | Phase 3 | Unknown | Apurano Pharmaceuticals GmbH | 558 | 2023-11-02 | 2024-01-31 |
| Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT MPL-001 (CBD: THC 25:1), Placebo oil for oral use - Knee Osteoarthritis | Phase 3 | Completed | McMaster University | 39 | 2023-05-03 | 2026-10-22 |
| Alcohol Use Disorder and Cannabidiol Cannabidiol, Placebo - Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 180 | 2023-04-30 | 2026-06-15 |
| Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND) Cannabis Derivatives, Placebo, Hormonal Contraceptive Agents - Endometriosis, Pelvic Pain | Phase 2 / Phase 3 | Terminated | University of Sao Paulo | 50 | 2023-01-03 | 2025-04-02 |
| Characterization of the Pharmacodynamic Response to Vaped THC THC or Placebo - Vaping, THC | Phase 3 | Withdrawn | Massachusetts General Hospital | 2022-11-01 | 2022-02-11 | |
| CANPAIN Feasibility Study Pragmatic Real World Trial Investigating CBMP in Chronic Pain Patients Cannabis - Chronic Pain | Phase 3 | Unknown | Harley Street (CPC) Limited | 100 | 2022-03-15 | 2022-03-18 |
| Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Cannabidiol (CBD) Oil Capsules, Sunflower Lecithin Oil in Capsule - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Unknown | McMaster University | 50 | 2021-12-15 | 2023-02-14 |
| Droperidol on Prevention of Cannabis Hyperemesis Syndrome Droperidol Injectable Product, Diphenhydramine - Cannabis Hyperemesis Syndrome | Phase 3 | Unknown | Mercy Health Ohio | 45 | 2021-12-02 | 2023-01-20 |
| Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose), Placebo Oil - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Withdrawn | McMaster University | 2021-04-01 | 2021-03-24 |
Showing 20 of 47. Sign in to see all of them.
Agnosia (10) · Chronic Pain (9) · Pain (8) · Somatoform Disorders (8) · Neuralgia (4) · Peripheral Nervous System Diseases (4) · Alcoholism (3) · Anxiety Disorders (3) · Multiple Sclerosis (3) · Substance-Related Disorders (3) · Agoraphobia (2) · Attention Deficit Disorder with Hyperactivity (2) · Autism Spectrum Disorder (2) · Autistic Disorder (2)
Chemically-Induced Disorders (47) · Mental Disorders (47) · Substance-Related Disorders (44) · Pathological Conditions, Signs and Symptoms (18) · Nervous System Diseases (17) · Neurologic Manifestations (17) · Signs and Symptoms (17) · Neurobehavioral Manifestations (12) · Perceptual Disorders (10) · Neuromuscular Diseases (7) · Central Nervous System Diseases (6) · Pathologic Processes (6) · Behavior (5) · Trauma, Nervous System (5) · Wounds and Injuries (5)
nabiximols (6) · Dronabinol (5) · Cannabidiol (4) · Medical Marijuana (4) · nabilone (3) · Acetylcysteine (2) · Therapeutics (2) · Behavior Therapy (1) · Cannabinoids (1) · Cannabinol (1) · Capsules (1) · Clonidine (1) · Contraceptive Agents, Hormonal (1) · Diphenhydramine (1) · Droperidol (1)
Apurano Pharmaceuticals GmbH (8) · McMaster University (3) · Fenix Innovation Group (2) · Mclean Hospital (2) · Medical University of Silesia (2) · Medical University of South Carolina (2) · New York State Psychiatric Institute (2) · Assaf-Harofeh Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Barth Wilsey (1) · Boston Children's Hospital (1) · Butler Hospital (1) · Colorado State University (1) · Denise Walker (1) · Hadassah Medical Organization (1)
United States (15) · Germany (9) · Canada (7) · Australia (2) · Israel (2) · Poland (2) · Brazil (1) · Denmark (1) · France (1) · Hong Kong (1) · Italy (1) · United Kingdom (1)
Kevin M Gray, MD (2) · Kevin P Hill, MD, MHS (2) · Michael Van Ameringen, MD, FRCPC (2) · Albert KK Chung, MBBS(HK) (1) · Amit Atrey, MD (1) · Anthony Adili, MD, P.Eng (1) · Barth Wilsey, MD (1) · Danielle Andrade, MD (1) · Denise D Walker, PhD (1) · Eden Evins, MD, MPH (1) · Eva Hoch, PhD (1) · Frances R Levin, M.D. (1) · Gerhard Buehringer, PhD (1) · Giancarlo Comi, MD (1) · Giovanni Marotta, MD (1)
PMID 21185685, PMID 23795877, PMID 24176199, PMID 24439950, PMID 28623823, PMID 28782982, PMID 28847455, PMID 29457671, PMID 30554828, PMID 31712969, PMID 34197135, PMID 35084903, PMID 35201607, PMID 39910268, PMID 41698715, PMID 42032682
K99DA029115 (1), P50DA009236 (1), R01AA012178 (1), R01AA029606 (1), R01DA012234 (1), R01DA014296 (1), R01DA018954 (1), R01DA030424 (1), R01DA039264 (1), U01DA031784 (1), U10DA013045 (1), U10DA013727 (1), U10DA013732 (1), U10DA015815 (1), U10DA015831 (1)